RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...
InvestorsHub on MSN

RedHill Biopharma shares jump on progress toward treating GLP-1 side effects

RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 16.5% in premarket trading on Monday after the company reported advances ...

Redhill Biopharma stock soars on GLP-1 side effect treatment progress

According to RedHill, while over 2% of Americans take GLP-1 receptor agonists, estimates suggest up to 50% discontinue treatment within three months due to side effects. Goldman Sachs estimates this ...
News Medical

Ondansetron Viatris

Please read this leaflet carefully before you use ONDANSETRON VIATRIS solution for injection. This leaflet answers some common questions about ONDANSETRON VIATRIS. It does not contain all the ...
Newsday

Limits to anti-nausea pill coverage wear on cancer patients and doctors

Cancer patients can ward off waves of vomiting after treatment with a relatively cheap anti-nausea pill, but some are running into coverage limits. Doctors say restrictions on the number of tablets ...
Hosted on MSN

Why Can’t We All Have Zofran?

Mention the anti-nausea medication Zofran in conversation, and like me, you may find that just about everyone you know has a story about it. My friend Laura says her husband keeps a stockpile for his ...